Increasing Physical Activity to Prevent Weight Regain After Bariatric Surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to determine if a psychological intervention can enhance physical activity levels and prevent weight regain in adults who have undergone metabolic bariatric surgery. Participants will be assigned to either an Acceptance and Commitment Therapy (ACT)-based intervention or an educational control group, engaging in online workshops, homework assignments, and individual support calls over 12 months. The study will assess the effectiveness of the psychological approach in fostering internal motivation for physical activity and managing the discomfort associated with it. By comparing the two interventions, researchers hope to identify a more effective strategy for long-term weight maintenance post-surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Having undergone either a primary Roux-en-Y gastric bypass or sleeve gastrectomy bariatric procedure between 6 and 20 months prior to enrollment
* Have reached their nadir weight and regained less than 10% of maximum weight lost based on weight measurements
* Had their surgery performed at Hartford Hospital or another surgical weight loss center within the Hartford HealthCare system.
* Able to provide consent
* Willing to engage in and complete the study protocol
* Able to safely participate in a physical activity program

Exclusion Criteria:

* Have regained 10% or more of maximum weight lost based on weight measurements
* Cannot ambulate independently
* Do not speak/read English at a 6th grade level
* Are pregnant, lactating, less than 6-months postpartum or plan to become pregnant during the course of the study
* Report current involvement in a weight management program outside of standard care
* Begin taking a newly prescribed medication for weight loss less than two months prior to study enrollment
* Begin taking a newly prescribed medication or change the dosage/frequency of pre-existing medications that are associated with weight loss/weight gain but not taken to produce weight loss less than two months prior to study enrollment
* Report any conditions or plans that would preclude adherence to the study protocol (i.e., plans to relocate, psychiatric problems such as substance use disorder, or terminal illness)

Where it's running

• Hartford HealthCare
  Hartford, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Dale S Bond, PhD — Hartford Hospital
• Study coordinator: Chloe David, B.S.
• Email: Chloe.David@hhchealth.org
• Phone: 860-972-5750

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.